Blockchain Registration Transaction Record

Viromed Advances Cold Plasma Products, Confirms 2026 Guidance

Viromed Medical AG reports H1 2026 progress: cold plasma pipeline, ViroCAP® med approval, revenue up to €2.5M, and confirms full-year guidance.

This news matters because Viromed's progress in cold plasma technology could lead to innovative medical treatments, particularly with PulmoPlas® and ViroCAP® med, offering new options for patients and healthcare providers. The successful MDR certification of ViroCAP® med and the exclusive veterinary partnership signal growing market acceptance, while the strong equity ratio and revenue growth indicate financial stability and potential for investors. As cold plasma gains scientific validation, it may revolutionize wound care and respiratory therapies, impacting a broad range of medical fields.